A
Alasdair M. Barr
Researcher at University of British Columbia
Publications - 231
Citations - 7960
Alasdair M. Barr is an academic researcher from University of British Columbia. The author has contributed to research in topics: Antipsychotic & Clozapine. The author has an hindex of 45, co-authored 211 publications receiving 6915 citations. Previous affiliations of Alasdair M. Barr include UBC Hospital & Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model
Heidi N. Boyda,Lurdes Tse,Ric M. Procyshyn,Daniel Wong,Tony K.Y. Wu,Cathy C. Pang,Alasdair M. Barr +6 more
TL;DR: It is indicated that acute administration of antipsychotic drugs has potent effects on metabolic regulation of glucose and insulin sensitivities, which may contribute to metabolic side-effects seen in humans.
Journal ArticleDOI
A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests.
Alasdair M. Barr,Jefferson W. Kinney,Matthew N. Hill,Xiaoying Lu,Shannon M. Biros,Julius Rebek,Tamas Bartfai +6 more
TL;DR: A novel galanin receptor type-3 (GalR3) antagonist is evaluated in preclinical tests of anxiety and depression and combined data from two species indicate that GalR3 receptor antagonists may exhibit antidepressant-like effects.
Journal ArticleDOI
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease
Jeremy M. Van Raamsdonk,Jacqueline Pearson,Daniel A. Rogers,Ge Lu,Vilte E. Barakauskas,Alasdair M. Barr,William G. Honer,Michael R. Hayden,Blair R. Leavitt +8 more
TL;DR: Oral delivery of ethyl-EPA to symptomatic YAC128 mice beginning at 7 months of age increased membrane EPA levels 3-fold and resulted in a modest but significant improvement in motor dysfunction by 12 years of age, indicating no reduction of striatal neuropathology.
Journal ArticleDOI
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
TL;DR: The update of evidence behind the classification of antipsychotic induced DSP and an investigation of its relationship to treatment resistance are reviewed.
Journal ArticleDOI
Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
TL;DR: The hypothesis that interleukin-18 (IL-18) plays a role in the microglial activation and dopaminergic neurodegeneration in substantia nigra pars compacta following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment in wild type and IL-18 knockout mice is tested.